Introduction
The crucial role of platelets in hemostasis is evident in patients with thrombocytopenia accompanied by serious bleeding complications. Thrombocytopenia is a serious side-effect of myelosuppressive/myeloablative chemoradiotherapy and the hematopoietic disorder immune thrombocytopenia (ITP). The development of platelet transfusion was therefore a milestone in cancer treatment.
Although platelet transfusion has been improved over the years, a major complication remains their storage at room temperature, which leads to bacterial growth and deterioration of platelet function. To be clinically effective, transfused platelets must circulate and function, that is prevent or stop bleeding. Currently, the gold standard test to evaluate transfused platelet products is in-vivo circulation and count increment of transfused radiolabeled platelets [1] . It is assumed that if a platelet product circulates normally, it should function appropriately. However, both parameters fail to assess the functional quality of transfused platelets.
Our understanding of factors that dictate platelet survival remains poor, as the discovery of novel and unexpected platelet clearance mechanisms shows. This review will focus on new lectin-carbohydrate-mediated platelet clearance mechanisms.
The classical pathway: antibody-mediated platelet clearance
Until recently the only well established platelet clearance mechanisms were antibody-mediated clearance and platelet consumption due to massive blood loss. In ITP, an auto-antibody (usually of the IgG class) binds to circulating platelets with specificity for membrane glycoproteins [2, 3, 4 ] . In children, most cases of ITP are acute, manifesting a few weeks after a viral illness [5, 6] . In adults, most cases of ITP are chronic, manifesting with an insidious onset [7]. These clinical presentations suggest different triggering events. In persons with chronic ITP, the majority of auto-antibodies are directed against the integrin aIIbb3 (GPIIb-IIIa) or the von Willebrand factor (VWF) receptor GPIb-IX-V [2, 3, 8] . Purpose of review Blood platelets are involved in primary and secondary hemostasis and thus maintain the integrity of the vasculature. They circulate with an average lifespan of 5-9 days in humans. Thus, the body must generate and clear platelets daily to maintain normal physiological blood platelet counts. Known platelet clearance mechanisms include antibody-mediated clearance by spleen macrophages, as in immune thrombocytopenia, and platelet consumption due to massive blood loss.
Recent findings
New concepts in the clearance mechanisms of platelets have recently emerged. New evidence shows that platelets desialyted due to chilling or sepsis are cleared in the liver by macrophages, that is Kupffer cells, as well as hepatocytes, through lectinmediated recognition of platelet glycans. On the contrary, platelet-associated antibodies normalize the clearance of platelets in a mouse model for Wiskott-Aldrich syndrome.
Summary
The goal of this review is to summarize the latest findings in platelet clearance mechanisms with a focus on lectin-mediated recognition of platelet glycans. Transfusion medicine and treatments of hematopoietic disorders associated with severe thrombocytopenia may benefit from a better understanding of these mechanisms. The coating of platelets with IgGs renders them susceptible to opsonization and Fc receptor-mediated phagocytosis by mononuclear macrophages, primarily but not exclusively in the spleen [9] . It is assumed that platelet auto-antibodies are formed in the white pulp of the spleen and mononuclear macrophages in the red pulp destroy IgG-coated platelets [10] . The slow passage of platelets through splenic sinusoids with a high local concentration of antibodies and low-affinity macrophage Fc (FcgRIA, IIA, and IIIA) or complement (CR1 and CR3) receptors promotes platelet phagocytosis and destruction (Fig. 1 ). The best evidence that the spleen plays an important role in the removal of auto-antibodycoated platelets comes from ITP patients who have undergone splenectomy, a procedure that results in restoration of normal platelet counts in most, but not all cases [11] .
The IgG auto-antibodies are also thought to damage megakaryocytes, the platelet precursors. However, this mechanism may only slightly contribute to the decrease in platelet counts in ITP [12] . The stimulus for autoantibody production in ITP is probably due to abnormal T cell activity [13] . The exact mechanisms of antibodymediated platelet clearance remain unclear.
The novel pathway: lectin-carbohydratemediated platelet clearance
For decades, all platelet products have been stored at room temperature, limiting platelet storage to 5 days because of the risk of bacterial growth and loss of platelet functionality [14] . Platelet refrigeration remains impossible because once chilled platelets are rapidly removed from the circulation. This odd clearance phenomenon has had profound consequences for blood banking. We have been investigating this clinically relevant problem of why refrigerated platelets fail to circulate for almost a decade and have defined two previously unsuspected, carbohydrate-dependent platelet clearance mechanisms (for review see [15] ).
We disproved the notion that chilled platelets are cleared because they undergo an extensive shape change when exposed to low temperatures and become trapped in the vasculature [16] . Cooling of platelets induces progressive clustering of glycan-bearing receptors, which causes lectins on macrophages and, unexpectedly, on hepatocytes to recognize chilled platelets.
The macrophage aMb2 integrin
The macrophage aM-lectin recognizes clustered GPIba subunits of the VWF receptor complex following hours of cooling, which results in the phagocytosis and clearance of platelets by liver macrophages, that is Kupffer cells, in vivo in mice and in vitro by human THP-1 macrophages. Subsequent work narrowed recognition of chilled platelets by aMb2 receptors to GPIba glycans with exposed b-N-acetylglucosamine (bGlcNAc) residues [17] . The finding of exposed incomplete glycans on surfaces of circulating platelets is surprising, as sialic acid generally caps glycans. Removal of sialic acid (desialylation) exposes galactose and degalactosylation reveals bGlcNAc. Although resting platelets contain some glycans with exposed bGlcNAc residues, refrigerated platelets have markedly increased bGlcNAc exposure. This altered epitope presentation, possibly induced by cooling and clustering of exposed bGlcNAc on GPIba facilitates lectin recognition and removal of refrigerated platelets [16, 17] . The mechanism of bGlcNAc exposure on circulating platelets remains unclear. However, mice deficient for aM-lectin have slightly higher platelet counts [16] , which suggests that the platelets lose sialic acid and galactose residues while circulating and the aM-lectin removes platelets with incomplete glycans from the circulation, thereby controlling platelet survival in vivo.
We attempted to rescue the clearance of chilled platelets by covering exposed bGlcNAc residues with galactose. Indeed, survival of platelets chilled for hours was markedly increased following galactosylation by functional galactosyltransferase(s) expressed by platelets [17] . Galactosylation therefore provided a simple approach to improve refrigerated platelet circulation. However, while depriving the aMb2 lectin-domain of its bGlcNAc ligand on refrigerated platelets, galactosylation theoretically provides a new Platelets bearing incomplete glycans are recognized by either liver macrophages or hepatocyte lectins, which leads to their clearance. IgG-coated platelets are phagocytized by both the Fc and complement receptors in the spleen. IgGs may recognize both amino acid and glycan residues. On the contrary, the binding of immune complexes, for example IgAs, to platelets prevents their rapid clearance.
ligand for asialoglycoprotein receptors. Hence, it was surprising that refrigerated mouse platelet circulation could be improved by galactosylation. However, the small amount of added galactose does not engage galactose lectin expressed on phagocytes.
Subsequently, a phase I clinical trial administering autologous, radiolabeled galactosylated apheresis platelets refrigerated for 2 days to human volunteers clearly showed that the galactosylation procedure did not extend platelet survival [18] . Similar data were found for mice. Evidently, different mechanisms are involved in the clearance of platelets refrigerated for hours or days.
The Ashwell-Morell receptor
We found that platelets refrigerated for days (designated below as long-term refrigerated platelets) are also removed from the recipients' circulation by the liver [19, 20 ] . Unexpectedly, hepatocytes, not Kupffer cells, ingested long-term refrigerated platelets [20 ] . How do hepatocytes recognize and ingest platelets? Masking of bgalactose (bGal) terminating oligosaccharide chains by sialic acid prevents recognition by galactose recognizing lectin receptors, lectins abundantly expressed on macrophages and hepatocytes. The hepatic lectin (Ashwell-Morell receptor) mediates the binding and removal of glycoconjugates with exposed bGal and GalNAc.
Long-term refrigerated platelets have increased bGal exposure, which provides a ligand for hepatic lectin receptors. Indeed, long-term refrigerated platelet recovery and survival are significantly improved in mice lacking hepatic lectin receptors [20 ] . Not surprisingly, longterm refrigerated and galactosylated platelets are cleared slightly faster independent of macrophage depletion [20 ] . In long-term refrigerated platelets, the mechanism of bGal exposure remains undetermined. However, it appears that most glycans with exposed bGal are associated with GPIba. Does the bGal-bearing GPIba presentation influence platelet clearance? We observed increased clustering of GPIba with prolonged refrigeration [20 ] . Hence, clustering of GPIba glycans on the surface of chilled platelets might amplify the galactose signal, thus enhancing Ashwell-Morell receptor avidity and binding, as reported earlier for bGlcNAc [17] . However, the functional relationship between GPIba clustering and platelet clearance by hepatic lectin remains unclear.
Platelet sialic acid
These results point to the critical role of glycans, specifically on GPIba, in platelet clearance. Experiments using mice lacking a2-3-sialyltransferase (ST3GalIV) activity further support this notion. ST3GalIV-null platelets have exposed bGal on their surface [21, 22, 23 ] and are also cleared by Ashwell-Morell receptors [20 ] . GPIba on ST3GalIV-null platelets is the major counter receptor for galactose-recognizing lectins. Taken together, our studies, as well as a recent report by Grewal et al. [20 ,21] point out the importance of a hepatic-based platelet removal system that uses Ashwell-Morell receptors to remove platelets expressing desialylated glycans on their surface.
Transfused fresh mouse wild-type platelets circulate longer in mice deficient for Ashwell-Morell receptors [20 ] , which suggests that hepatocytes also remove senile, desialylated platelets. As platelets lose sialic acid from membrane glycoproteins during aging and circulation, enhanced exposure of nonsialylated glycan chains may represent a physiological phenomenon that triggers clearance of senescent blood cells [24] . Further supporting this notion, mice lacking hepatic lectin receptors have higher platelet counts and their platelets are deficient for sialic acid (unpublished data). Similar to erythrocytes, invitro desialylated platelets are cleared rapidly from the circulation [25, 26] .
Are glycoproteins other than GPIba involved in the clearance of chilled platelets? VWF binding increases during platelet storage [20 ] . It appears that preferentially desialylated VWF binds to long-term refrigerated platelets, indicating that desialylation of VWF molecules may promote binding to GPIba. In support of this idea, we found that binding of deficiently sialylated VWF, derived from ST3Gal-IV-null plasma, to WT platelets is enhanced both in vitro and in vivo [23 ] . Proteolytic removal of the GPIba N-terminal region deprives GPIba of its VWF-binding domain and bound VWF. Whether VWF glycans contribute to recognition of platelets by Ashwell-Morell receptors is unclear.
The role of macrophages
Macrophages do not phagocytize long-term refrigerated desialylated platelets. However, our studies revealed that macrophages rapidly (hours) remove approximately 40% of transfused fresh room temperature platelets, implying that macrophages detect 'damage' inflicted during platelet isolation, a loss which is consistently observed following transfusion of fresh human platelets into healthy volunteers [18] . It is possible that macrophages recognize damaging events acutely inflicted to platelets, including antibody binding. On the contrary, hepatocytes could control the removal of senile platelets and daily platelet turnover. In support of this hypothesis, we showed that transfused fresh platelets circulate normally in macrophage-depleted mice [20 ] . It is tempting to speculate that platelet membrane or associated glycoproteins, for example antibodies or other plasma proteins, mediate clearance through both Fc receptors and lectins on macrophages. On the contrary, bound glycoproteins could shield platelets from recognition through phagocytic receptors.
Wiskott-Aldrich syndrome
Wiskott-Aldrich syndrome (WAS) is a recessive hematopoietic disorder characterized by immunodeficiency, eczema, and severe microthrombocytopenia [27] . Xlinked thrombocytopenia (XLT) is a milder phenotype [28 ] . The WASP gene implicated in WAS and XLT encodes a protein of 502 amino acids and 64 kDa, called WAS protein (WASp), a key regulator of actin assembly in hematopoietic cells. The mechanisms of WAS-associated thrombocytopenia are poorly understood, although increased platelet destruction by the spleen is believed to play a major role. Platelets isolated from WAS patients or WASp-null mice function normally [29, 30] . Furthermore, megakaryocytes isolated from WAS patients form proplatelets normally and produce platelets of normal size in vitro [31] . Premature proplatelet formation and platelet production are observed in the bone marrow compartment of WASp-null mice [32] . On the contrary, WAS platelets are cleared rapidly from circulation when transfused autologously [33, 34] . Similarly, mice lacking WASp or the WASp-interacting protein (WIP) have moderate thrombocytopenia due in part to increased platelet clearance [35, 36 ] . WIP and WASp form a tight complex in platelets. WIP-null platelets lack WASp and thus are double deficient [36 ] . WIP-null mice have a phenotype closer to that of WAS than WASp-null mice [37] .
Studies suggest an antibody-mediated platelet clearance in WAS, similar to that of ITP. Platelet-associated antibodies are often observed in WAS patients, a phenotype that improves after splenectomy, as do low platelet count and small platelet size [38, 39] . However, most WIP-null, but not WASp-null, mice evolve platelet-associated antibodies of the IgA class, which diminish their biological functions initiated by the collagen receptor GPVI but normalize their platelet survival [36 ] . Thus, plateletassociated antibodies protect against rather than mediate the increased clearance of WIP-null platelets. The reason for IgA binding to WIP-null platelets is unclear. WIP-null mice evolve IgA-mediated glomerular nephropathy [37] , as do WAS and XLT patients [40, 41] , and may have circulating IgA complexes that bind to platelets. We speculate that IgAs may directly block binding sites for immune cells and/or the clearance system becomes initially saturated and therefore inhibited by high levels of platelet-bound IgAs.
Surface glycans are possible targets for removal of WAS platelets. Glycosylation defects are associated with WASp deficiency. For example, CD43 (leukosialin, sia-lophorin) is abnormally O-glycosylated in lymphocytes isolated from WAS patients [42] [43] [44] . WAS lymphocytes and platelets have increased expression and activity of the core 2 GlcNAc transferase and the a2-6-sialyl transferase [45, 46] . Furthermore, the gene encoding the UDPgalactose translocator, also impaired in WAS, is located on the Xp11.22-p11.23 locus of the X chromosome, which also contains the WASP gene [47] . Whether platelet glycosylation defects are involved in the severe thrombocytopenia associated with WASp deficiency remains to be determined.
Conclusion
By addressing the problem of platelet storage, we have defined two carbohydrate-mediated platelet clearance mechanisms. One potential implication of our findings is that addition of sialic acid together with galactose may prove successful in allowing chilled platelet circulation or may ameliorate the deterioration of room temperature stored platelets. The mechanism of how platelets lose sialic acid or galactose during storage, that is whether plasma-derived or platelet-derived glycosidases mediate the removal of glycan residues, is unclear. Inhibition of glycosidases would offer another feasible approach to prevent platelet clearance following cooling.
It is likely that hematopoietic disorders, such as ITP and WAS, are due to deteriorated glycans recognized by antibodies leading to platelet clearance. Understanding the role of glycans in platelet survival and function will provide a new dimension to platelet homeostasis under normal and disease conditions, including immune or cardiovascular disorders. Novel therapies in which glycans, rather than proteins, are modulated may become a useful tool to improve platelet circulation and function.
The potential role of hepatocytes in removal of senile/ desialylated platelets is intriguing. Hepatocytes may modulate daily platelet turnover, thereby regulating or promoting platelet production in the bone marrow.
